Comparing a new drug to topotecan for relapsed small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called HS-20093 against a standard drug (topotecan) for people with small cell lung cancer that has returned after initial treatment. The goal is to see which drug works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with small cell lung cancer.
- Your cancer got worse after or during your first round of treatment that included platinum drugs.
- You have at least one tumor that can be measured on scans.
- You are able to take care of yourself (ECOG 0-1).
- You have not received certain prior treatments like anti-B7-H3 drugs or topoisomerase I inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, JK-1201I, against a standard treatment (topotecan) for people with extensive-stage small cell lung cancer that came back after platinum-based chemotherapy. It aims to see if the new drug works better at controlling the cancer.
This trial tests whether adding IBB0979 (an experimental immunotherapy) to standard chemotherapy (topotecan) works better than topotecan alone for people whose small cell lung cancer has returned or worsened after prior treatment. It aims to find a new option for patients who have limited options.
This study compares a new drug called ZG006 against standard chemotherapy for people with small cell lung cancer that has come back after prior treatment. The goal is to see if ZG006 works better or has fewer side effects.
This trial tests a new drug, NMS-03305293, in adults with small cell lung cancer that has come back after earlier treatments. The goal is to see if it can help shrink or slow the cancer.
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
This trial tests a new drug called ABBV-706 against standard treatments (topotecan, lurbinectedin, or amrubicin) for people with small cell lung cancer that has come back or stopped responding to previous therapies. The goal is to see if ABBV-706 works better at controlling the cancer.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.